NCT01395602

Effect of Cabergoline on Weight and Glucose Tolerance

Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Columbia University · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Conditions

• Body Weight
• Impaired Glucose Tolerance in Obese

Interventions

Type	Name	Description
DRUG	Cabergoline	cabergoline 0.5 mg twice weekly
OTHER	placebo	1 pill twice weekly

Timeline

• Start date: 2002-04-01
• Primary completion: 2003-09-01
• Completion: 2011-07-01
• First posted: 2011-07-15
• Last updated: 2015-10-14

Locations

1 site across 1 country: United States